[go: up one dir, main page]

MX2018010125A - Procedimientos de tratamiento de leucemia mieloide aguda. - Google Patents

Procedimientos de tratamiento de leucemia mieloide aguda.

Info

Publication number
MX2018010125A
MX2018010125A MX2018010125A MX2018010125A MX2018010125A MX 2018010125 A MX2018010125 A MX 2018010125A MX 2018010125 A MX2018010125 A MX 2018010125A MX 2018010125 A MX2018010125 A MX 2018010125A MX 2018010125 A MX2018010125 A MX 2018010125A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
acute myeloid
subject
density
treatment procedures
Prior art date
Application number
MX2018010125A
Other languages
English (en)
Inventor
Peled Amnon
Pereg Yaron
Original Assignee
Biolinerx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolinerx Ltd filed Critical Biolinerx Ltd
Publication of MX2018010125A publication Critical patent/MX2018010125A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento de tratamiento de leucemia mieloide aguda (LMA), que incluye las etapas de (i) medir la densidad de células blásticas en la sangre periférica y la médula ósea de un sujeto con LMA; (ii) administrar al sujeto un antagonista de CXCR4; y (iii) administrar al sujeto una cantidad terapéuticamente eficaz del antagonista de CXCR4 y una cantidad terapéuticamente eficaz de un agente quimioterapéutico, si la densidad de células blásticas en la sangre periférica es menor que el 10% del total de leucocitos periféricos, o al menos cinco veces menor que la densidad de células blásticas en la médula ósea, o al menos dos veces mayor un día o más después de la etapa (ii).
MX2018010125A 2016-02-23 2017-02-23 Procedimientos de tratamiento de leucemia mieloide aguda. MX2018010125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298563P 2016-02-23 2016-02-23
PCT/IL2017/050232 WO2017145161A1 (en) 2016-02-23 2017-02-23 Methods of treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2018010125A true MX2018010125A (es) 2019-03-28

Family

ID=59684875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010125A MX2018010125A (es) 2016-02-23 2017-02-23 Procedimientos de tratamiento de leucemia mieloide aguda.

Country Status (12)

Country Link
US (1) US10993985B2 (es)
EP (1) EP3419645B1 (es)
JP (1) JP6676182B2 (es)
KR (1) KR102033920B1 (es)
CN (1) CN109310733A (es)
AU (1) AU2017222495B2 (es)
BR (1) BR112018016924A2 (es)
CA (1) CA3014530A1 (es)
ES (1) ES2830726T3 (es)
IL (1) IL261160B (es)
MX (1) MX2018010125A (es)
WO (1) WO2017145161A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP6676182B2 (ja) 2016-02-23 2020-04-08 バイオラインアールエックス・リミテッドＢｉｏＬｉｎｅＲｘ Ｌｔｄ． 急性骨髄性白血病の治療方法
BR112021017537A2 (pt) 2019-03-05 2021-12-14 Nkarta Inc Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia
US20220387358A1 (en) * 2019-11-08 2022-12-08 University Of Virginia Patent Foundation Ceramide analog saclac modulates sphingolipid levels and mcl-1 splicing to induce apoptosis in acute myeloid leukemia
EP4619010A2 (en) * 2022-11-16 2025-09-24 Nkarta, Inc. Dosing regimens for combination therapies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS552602A (en) 1978-06-20 1980-01-10 Yamasa Shoyu Co Ltd 1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
WO1986004605A1 (fr) 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Facteur de stimulation de colonies de granulocytes humains
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0396158A1 (en) 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (de) 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
ES2039209T5 (es) 1986-01-22 1996-07-16 Chugai Pharmaceutical Co Ltd Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.
CA1297005C (en) 1986-01-22 1992-03-10 Masahiko Tamura Pharmaceutical agent for the treatment of myelogenous leukemia
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
DK174044B1 (da) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ES2063783T3 (es) 1988-06-03 1995-01-16 Chugai Pharmaceutical Co Ltd Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion.
US5202117A (en) 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
WO1995010534A1 (en) 1993-10-14 1995-04-20 Seikagaku Corporation Polypeptide and anti-hiv agent prepared therefrom
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5492126A (en) 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
JP2002505596A (ja) 1997-05-23 2002-02-19 トランサージカル，インコーポレイテッド Ｍｒｉ誘導治療装置及び方法
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
EP1061944B1 (en) 1998-03-13 2004-01-28 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6294459B1 (en) 1998-09-03 2001-09-25 Micron Technology, Inc. Anti-reflective coatings and methods for forming and using same
HK1039749B (zh) 1998-10-05 2007-10-05 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
US6576875B1 (en) 1998-10-27 2003-06-10 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E. V Method and device for controlling a targeted thermal deposition into a material
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AU773437C (en) 1999-03-29 2005-02-17 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
EP2261256A3 (en) 1999-11-24 2011-03-02 Schering Corporation Methods of inhibiting metastasis
WO2001064716A1 (fr) 2000-03-03 2001-09-07 Nobutaka Fujii Composes antiviraux
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
JP4808363B2 (ja) 2000-09-05 2011-11-02 バイオカイン セラピューティックス リミテッド 新規ポリペプチド及びこれを含む抗ｈｉｖ剤
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (ja) 2001-02-16 2003-02-10 サンケン電気株式会社 スイッチング電源装置
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
JP4781621B2 (ja) 2002-08-27 2011-09-28 バイオカイン セラピューティックス リミテッド Ｃｘｃｒ４拮抗薬およびその用途
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2006524242A (ja) 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
DK1726310T3 (da) 2004-03-19 2012-05-07 Morinaga Milk Industry Co Ltd Lægemiddel til cancerterapi
EP1796716A4 (en) 2004-08-13 2010-09-08 Anormed Inc COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
CA2649253A1 (en) 2005-05-25 2006-11-30 Hadasit Medical Research Services & Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
EP1951046B1 (en) 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
WO2007067280A2 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
EP2489728A1 (en) 2006-06-15 2012-08-22 Neostem, Inc Processing procedure for peripheral blood stem cells
MX2009001272A (es) 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
US7968098B2 (en) 2006-08-04 2011-06-28 Kurume University HLA-A24-binding KIF-derived peptide
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
EP2243833A1 (en) * 2009-04-22 2010-10-27 Erasmus University Medical Center Rotterdam Method for the treatment of acute myeloid leukemia
EP2442822B1 (en) 2009-06-14 2014-03-05 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2010146584A1 (en) 2009-06-15 2010-12-23 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
WO2011069121A1 (en) 2009-12-04 2011-06-09 Neostem, Inc. Mesenchymal stem cells (mscs) isolated from mobilized peripheral blood
US20120082687A1 (en) 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
US20130303460A1 (en) 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
HRP20182183T1 (hr) * 2011-11-09 2019-02-22 Bristol-Myers Squibb Company Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US20140147411A1 (en) 2012-11-14 2014-05-29 U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS Methods of treating cancer and testing mutation zygosity related thereto
MX363896B (es) * 2013-03-24 2019-04-05 Biokine Therapeutics Ltd Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.
JP2016531907A (ja) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
JP2016527303A (ja) 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
CN106029084A (zh) 2013-10-31 2016-10-12 百欧肯治疗有限公司 治疗具有类fms酪氨酸激酶3突变的急性骨髓性白血病的方法
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
US20180161366A1 (en) 2015-05-20 2018-06-14 Biokine Therapeutics Ltd. Methods of obtaining mononuclear blood cells and uses thereof
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP6676182B2 (ja) 2016-02-23 2020-04-08 バイオラインアールエックス・リミテッドＢｉｏＬｉｎｅＲｘ Ｌｔｄ． 急性骨髄性白血病の治療方法

Also Published As

Publication number Publication date
EP3419645B1 (en) 2020-09-02
IL261160A (en) 2018-10-31
US10993985B2 (en) 2021-05-04
CA3014530A1 (en) 2017-08-31
WO2017145161A1 (en) 2017-08-31
IL261160B (en) 2019-12-31
KR102033920B1 (ko) 2019-10-18
AU2017222495A1 (en) 2018-09-27
EP3419645A4 (en) 2019-10-16
KR20180115757A (ko) 2018-10-23
JP2019510005A (ja) 2019-04-11
CN109310733A (zh) 2019-02-05
AU2017222495B2 (en) 2019-08-08
EP3419645A1 (en) 2019-01-02
JP6676182B2 (ja) 2020-04-08
ES2830726T3 (es) 2021-06-04
BR112018016924A2 (pt) 2019-01-02
US20190046602A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
MX2018010125A (es) Procedimientos de tratamiento de leucemia mieloide aguda.
SA521421559B1 (ar) أجهزة قابلة للزرع للعلاج بالخلايا وطرق ذات الصلة
CO2017013432A2 (es) Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones
MX2007005200A (es) Plaquetas a partir de celulas germinales.
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
JP2017524031A5 (es)
MX2019014800A (es) Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
AR063470A1 (es) Terapia combinada
EA202190569A1 (ru) Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2024004652A (es) Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas.
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
EP2156843A3 (de) Verwendung von niedrig dosiertem Erythropoietin zur Behandlung von akuter oder chronischer Niereninsuffizienz und zur Behandlung von Wunden
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
IL257929B1 (en) Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
MX2021003798A (es) Terapia con celulas de placenta humana y celulas hematopoyeticas.
CL2025000438A1 (es) Composiciones farmacéuticas sólidas de adagrasib
Cormier Blind mole rats may hold key to cancer
AR112754A1 (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO
何雅利 Advanced Maternal Age and Severe Labor Pain Perception: A Hospital-Sponsored Quality Improvement Study
RU2013135817A (ru) Средство для лечения гнойно-воспалительных процессов мягких тканей и слизистых оболочек